The Lancet Oncology
Publisher: Elsevier · ISSN 1470-2045 · 93 articles
- Russia slashes federal cancer funding to spend on defence
- Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial
- Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial
- Assessment of comprehensiveness of national cancer control plans using a multiagent artificial intelligence model: a global analysis
- Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study
- Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial
- Global uptake of essential cancer medicines with and without complex genomic diagnostics: a retrospective observational study
- Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial
- Global health expenditures on cancer control: a cross-sectional analysis
- Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer
- Development of the Children's Oncology Group long-term follow-up guideline for cancer genetics evaluation in childhood cancer survivors
- Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations
- Estimated global treatment costs for 31 cancer types by stage, year, and follow-up period: a systematic review and modelling study
- Armamentarium of scientific tools enough to win cancer fight in the Commonwealth
- Small island developing states and the Commonwealth
- Survival in patients with renal cell carcinoma and brain metastases: an update of the Renal Graded Prognostic Assessment
- A council of the willing for cancer in the Commonwealth
- Turning shared inheritance into shared action
- Addressing gaps in cancer care in the Caribbean
- Cancer in the Commonwealth: a Lancet Oncology Commission
- The Commonwealth's cancer moment
- From Commonwealth ambition to African action on cancer
- Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial
- Co-targeting angiogenesis and immune checkpoints in breast cancer
- Kenya's new cancer treatment targets test health system capacity
- Mastering the role of radiotherapy in pancreatic ductal adenocarcinoma: who and why?
- Genomically matched targeted therapy for ovarian clear cell carcinoma
- Risovalisib for PIK3CA-mutated recurrent or persistent ovarian clear cell carcinoma: a single-arm, multicentre, phase 2 trial
- Türkiye Health Minister calls for stricter tobacco control measures
- Review recommends radical overhaul to multidisciplinary working in NHS cancer services